Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475208052> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2475208052 endingPage "e626" @default.
- W2475208052 startingPage "e626" @default.
- W2475208052 abstract "e626 Background: High dose rate (HDR) brachytherapy is an attractive treatment option for localized prostate cancer (CaP) as it allows for safe dose escalation and exploits the radiobiological advantage of using a high dose/fraction. We evaluate our early experience in using HDR monotherapy for localized CaP. Methods: Forty patients with low- to intermediate-risk CaP were treated from October 2013-July 2015. Patients had catheters placed transperineally under spinal anaesthesia, using transrectal ultrasound guidance. The clinical target volume [CTV: prostate ± seminal vesicles base] was outlined on a planning CT scan with the catheters and template in-situ. The CTV was grown by 3mm isotropically to obtain the planning target volume (PTV). The catheters were reconstructed and plan optimised according to pre-set dose constraints [DC]. Dose delivered was 19Gy/one fraction. Toxicity was assessed using RTOG criteria. Results: A range of volumes were implanted (20–120 cc, median: 37.5), using a median of 17 needles (range 13–20). Satisfactory implants were achieved in patients with volumes>60cc by excluding pubic arch interference on the pre-implant MRI pelvis. All patients were discharged home within 24 hours, with two patients (5%) requiring re-catheterisation. Good dose coverage to the PTV was achieved: median D90 of 20.4Gy (DC>19Gy), V100 of 95.1% (DC≥95%). Urethral and rectal sparing was satisfactory: urethral D10 of 21.23Gy (DC<22Gy), rectal D2cc of 14Gy (DC<15Gy). The median follow-up was 8 (1-22.6) months. Twenty-five patients, with at least 6 months follow-up showed a median PSA reduction of 80%. Thus far, one had biopsy proven recurrence. Only two patients had grade 3 urinary toxicity and one had grade 3 bowel toxicity at 2 weeks, which returned to baseline at 12 weeks. The IPSS score increased at 2-4 weeks after treatment, but returned to baseline after 3 months. Conclusions: Our initial experience with HDR monotherapy for localized CaP confirms this to be safe, with minimal acute complications. It is possible to implant volumes higher than 60cc, if adequate measures are taken. The early efficacy data for 19Gy is also promising." @default.
- W2475208052 created "2016-07-22" @default.
- W2475208052 creator A5004319544 @default.
- W2475208052 creator A5034586479 @default.
- W2475208052 creator A5053173599 @default.
- W2475208052 creator A5061221375 @default.
- W2475208052 creator A5070417221 @default.
- W2475208052 creator A5072785082 @default.
- W2475208052 creator A5091236832 @default.
- W2475208052 date "2016-01-10" @default.
- W2475208052 modified "2023-09-27" @default.
- W2475208052 title "High dose rate brachytherapy as monotherapy for localized prostate cancer: Our initial experience." @default.
- W2475208052 doi "https://doi.org/10.1200/jco.2016.34.2_suppl.e626" @default.
- W2475208052 hasPublicationYear "2016" @default.
- W2475208052 type Work @default.
- W2475208052 sameAs 2475208052 @default.
- W2475208052 citedByCount "1" @default.
- W2475208052 countsByYear W24752080522018 @default.
- W2475208052 crossrefType "journal-article" @default.
- W2475208052 hasAuthorship W2475208052A5004319544 @default.
- W2475208052 hasAuthorship W2475208052A5034586479 @default.
- W2475208052 hasAuthorship W2475208052A5053173599 @default.
- W2475208052 hasAuthorship W2475208052A5061221375 @default.
- W2475208052 hasAuthorship W2475208052A5070417221 @default.
- W2475208052 hasAuthorship W2475208052A5072785082 @default.
- W2475208052 hasAuthorship W2475208052A5091236832 @default.
- W2475208052 hasConcept C121608353 @default.
- W2475208052 hasConcept C126322002 @default.
- W2475208052 hasConcept C126838900 @default.
- W2475208052 hasConcept C126894567 @default.
- W2475208052 hasConcept C141071460 @default.
- W2475208052 hasConcept C19527891 @default.
- W2475208052 hasConcept C201645570 @default.
- W2475208052 hasConcept C2776235491 @default.
- W2475208052 hasConcept C2777416452 @default.
- W2475208052 hasConcept C2778357063 @default.
- W2475208052 hasConcept C2780192828 @default.
- W2475208052 hasConcept C2781411149 @default.
- W2475208052 hasConcept C2989005 @default.
- W2475208052 hasConcept C3017588741 @default.
- W2475208052 hasConcept C509974204 @default.
- W2475208052 hasConcept C71924100 @default.
- W2475208052 hasConcept C75088862 @default.
- W2475208052 hasConceptScore W2475208052C121608353 @default.
- W2475208052 hasConceptScore W2475208052C126322002 @default.
- W2475208052 hasConceptScore W2475208052C126838900 @default.
- W2475208052 hasConceptScore W2475208052C126894567 @default.
- W2475208052 hasConceptScore W2475208052C141071460 @default.
- W2475208052 hasConceptScore W2475208052C19527891 @default.
- W2475208052 hasConceptScore W2475208052C201645570 @default.
- W2475208052 hasConceptScore W2475208052C2776235491 @default.
- W2475208052 hasConceptScore W2475208052C2777416452 @default.
- W2475208052 hasConceptScore W2475208052C2778357063 @default.
- W2475208052 hasConceptScore W2475208052C2780192828 @default.
- W2475208052 hasConceptScore W2475208052C2781411149 @default.
- W2475208052 hasConceptScore W2475208052C2989005 @default.
- W2475208052 hasConceptScore W2475208052C3017588741 @default.
- W2475208052 hasConceptScore W2475208052C509974204 @default.
- W2475208052 hasConceptScore W2475208052C71924100 @default.
- W2475208052 hasConceptScore W2475208052C75088862 @default.
- W2475208052 hasIssue "2_suppl" @default.
- W2475208052 hasLocation W24752080521 @default.
- W2475208052 hasOpenAccess W2475208052 @default.
- W2475208052 hasPrimaryLocation W24752080521 @default.
- W2475208052 hasRelatedWork W1989080038 @default.
- W2475208052 hasRelatedWork W2023503398 @default.
- W2475208052 hasRelatedWork W2027294118 @default.
- W2475208052 hasRelatedWork W2039692113 @default.
- W2475208052 hasRelatedWork W2094494178 @default.
- W2475208052 hasRelatedWork W2139928071 @default.
- W2475208052 hasRelatedWork W2475208052 @default.
- W2475208052 hasRelatedWork W2515874139 @default.
- W2475208052 hasRelatedWork W2883141619 @default.
- W2475208052 hasRelatedWork W4234817787 @default.
- W2475208052 hasVolume "34" @default.
- W2475208052 isParatext "false" @default.
- W2475208052 isRetracted "false" @default.
- W2475208052 magId "2475208052" @default.
- W2475208052 workType "article" @default.